Pharmacally
Acne
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Acne
Health TidingsDenifanstat Cuts Acne Lesions by 72% at 52 Weeks, With 57% Treatment Success in Extension TrialSagimet Biosciences and Ascletis reported detailed 52-week Phase 3 extension results for denifanstat in moderate to severe acne, showing a 56.7% treatment success rate and substantial reductions in…Fact-Checked
Clinical TrialsDenifanstat Shows Sustained Efficacy Through 52 Weeks in Phase 3 Acne Extension StudySagimet Biosciences reported continued improvements across efficacy endpoints through 52 weeks with denifanstat in a Phase 3 extension study of moderate to severe acne, supporting plans for the…Fact-Checked
Health TidingsSagimet Receives FDA Clearance to Advance Phase 3 Denifanstat Acne TrialSagimet Biosciences has received FDA clearance and a “Study May Proceed” letter for its Phase 3 trial of oral FASN inhibitor denifanstat in moderate to severe acne.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.